reports
Aedifica NV/SA: Publication relating to a transparency notification
Aedifica NV/SA: Publication relating to a transparency notification Please find below a press release from Aedifica (a public regulated real estate company under Belgian law, listed on Euronext Brussels and Euronext Amsterdam), regarding a publication relating to a transparency notification. Attachments
- ING Helpdesk
- Hilde Van Boxstael
- Lynn Hautekeete
- Thibault Leneeuw
- Thomas Couvreur
- Adrian Pehl
- Emira Sagaama
- Emna Ben Bdira
- Marc Lavaud
- Maxime Kogge
- Roy Külter
MT ARCELORMITTAL SA
BEKB BEKAERT SA
AAL ANGLO AMERICAN PLC
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
RCO REMY COINTREAU SA
SBMO SBM OFFSHORE NV
ZVTG ZAVAROVALNICA TRIGLAV D.D.
SZG SALZGITTER AG
CGM CEGEDIM SA
VOE VOESTALPINE AG
ACX ACERINOX SA
WIZZ WIZZ AIR HOLDINGS PLC
ERA ERAMET SA
COFB COFINIMMO SA
NDA AURUBIS AG
AED AEDIFICA SA
SLIGR SLIGRO FOOD GROUP N.V.
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
CPINV CARE PROPERTY INVEST SA
BCHN BURCKHARDT COMPRESSION HOLDING AG
RIO RIO TINTO PLC
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
ALVGO VOGO SA
STM STABILUS SE
- Adrian Pehl
- Emira Sagaama
- Emna Ben Bdira
- Marc Lavaud
- Maxime Kogge
- Roy Külter
MT ARCELORMITTAL SA
BEKB BEKAERT SA
AAL ANGLO AMERICAN PLC
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
RCO REMY COINTREAU SA
SBMO SBM OFFSHORE NV
ZVTG ZAVAROVALNICA TRIGLAV D.D.
SZG SALZGITTER AG
BLC BASTIDE LE CONFORT MEDICAL SA
CGM CEGEDIM SA
VOE VOESTALPINE AG
ACX ACERINOX SA
ERA ERAMET SA
COFB COFINIMMO SA
NDA AURUBIS AG
AED AEDIFICA SA
SLIGR SLIGRO FOOD GROUP N.V.
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
CPINV CARE PROPERTY INVEST SA
BCHN BURCKHARDT COMPRESSION HOLDING AG
RIO RIO TINTO PLC
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
ALVGO VOGO SA
STM STABILUS SE
- Jan Frederik Slijkerman
- Jeroen van den Broek
- Jesse Norcross
- Nadège Tillier
- Timothy Rahill
- Wedbush Research
- Hilde Van Boxstael
- Lynn Hautekeete
- Wim Lewi
- Jacob Mekhael
Pharvaris R&D day outlines plans to expand deucrictibant opportunity
Yesterday, Pharvaris hosted an R&D call to discuss plans for deucrictibant (oral B2 receptor antagonist) beyond HAE type 1/2. The company believes that deucrictibant could offer good outcomes for patients with normal C1-INH HAE, and this subset of patients is included in the phase 3 programs for on-demand and prophylaxis. In addition, the company pointed to the potential of deucrictibant to address acquired angioedema (AAE), where no approved treatments exist and investigator results demonstrate...
- Dylan Shindler
- Laura Chico
- Gerardo Ibanez
- Roy Külter
- Steven Boumans
- ING Helpdesk
- Jan Frederik Slijkerman
- Jeroen van den Broek
- Jesse Norcross
- Nadège Tillier
- Timothy Rahill
- Guy Sips
- Jacob Mekhael
- Livio Luyten
- Lynn Hautekeete
- Thomas Vranken
- Wim Lewi
- Guy Sips
Floridienne Strong gains for Biotrop offset by greenhouse market press...
Floridienne reported, without giving exact numbers, 1Q25 sales growth driven by the exceptional momentum of Biotrop. recording a significant increase in both revenue and profitability thanks to the success of its biological solutions for open-field crops in the Brazilian market. At the same time BioFirst (previously known as BioBest) saw increased competition in North America in the greenhouse cultivation segment, impacting the profitability of its legacy activities. We maintain our € 835 TP and...
- ING Helpdesk
Benelux Morning Notes
Aedifica and Cofinimmo: Agreement reached to create Europe's leading Healthcare REIT. bpost: CMD press release; #Reshape 2029. D'Ieteren: Belgian new car registrations down 11.7% in May, VW down 13.5% Fugro: Meeting with CEO & IR; 2Q25 also has its challenges. UCB: Peer Moonlake held takeover talks with US Merck, FT reports
- Michiel Declercq
bpost Launches new 2024-2027 ambitions
Today, bpost launched its “Reshape 2029” strategy. This will be followed by a CMD in Brussels later today. Over the next years, bpost's intends to reposition itself as a logistics leader that also provides postal services. The transformation should result in group revenues exceeding € 5.0bn by 2027 (kbcse: € 4.8bn), with the adj. EBIT expected to progressively recover above € 275m (kbcse: € 208m). Growth is mainly expected to come from its 3PL business. While the outlook comes in comfortably abo...
- Jacob Mekhael
MaaT Pharma Completes EU regulatory submission for MaaT013 in aGvHD
MaaT announced the submission of the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its lead drug candidate MaaT013 (microbiome therapy, enema formulation) in aGvHD under the brand name Xervyteg. Potential approval could be granted in 2H26, and MaaT is actively exploring strategic partnerships to commercialise MaaT013 in Europe. We believe the solid phase 3 results and good uptake in the early access program will be supportive of MaaT013's commercial launch ...
- Jacob Mekhael
Pharvaris Supportive data at C1-Inhibitor Deficiency and Angioedema Wo...
Pharvaris provided a summary of data that was presented at the C1-Inhibitor Deficiency and Angioedema Workshop, held 29 May – 1 June. The presentations continue to be supportive of deucrictibant's differentiated profile in HAE and included i) data that supports dual use of B2 antagonism for LTP and ODT in the same patients, ii) limited symptom recurrence showing durability of on-demand treatment, as well as iii) a novel biomarker assay that could help identify BK mediated angioedema. We reiterat...
- Guy Sips
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.